Oral, but not transdermal, administration of estrogens lowers tissue-type plasminogen activator levels in humans without affecting endothelial synthesis.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Arteriosclerosis, Thrombosis and Vascular Biology

• Publication date

  2000-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/01.ATV.20.5.1396PMID 10807760
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women.

  1998cited by this paper
• The Effects of Sex Steroids on Plasma Levels of Marker Proteins of Endothelial Cell Functioning

  1998cited by this paper
• Oral estrogen improves serum lipids, homocysteine and fibrinolysis in elderly men.

  1998cited by this paper
• Visceral fat accumulation is an important determinant of PAI-1 levels in young, nonobese men and women: modulation by cross-sex hormone administration.

  1998cited by this paper
• Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women.

  1997cited by this paper
• Production of Plasminogen Activator Inhibitor 1 by Human Adipose Tissue: Possible Link Between Visceral Fat Accumulation and Vascular Disease

  1997cited by this paper
• Decreased half‐life time of plasma von Willebrand factor collagen binding activity in essential thrombocythaemia: normalization after cytoreduction of the increased platelet count

  1997cited by this paper
• Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex: relationship to elevated TPA antigen in patients with high PAI-1 activity levels.

  1997cited by this paper
• Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial.

  1997cited by this paper
• Enhanced expression of PAI–1 in visceral fat: Possible contributor to vascular disease in obeisty

  1996cited by this paper
• Postmenopausal estrogen and progestin use and the risk of cardiovascular disease.

  1996cited by this paper
• Reproducibility of Fibrinolytic Response to Venous Occlusion in Healthy Subjects

  1995cited by this paper
• Relationships of plasminogen activator inhibitor activity and lipoprotein(a) with insulin, testosterone, 17 beta-estradiol, and testosterone binding globulin in myocardial infarction patients and healthy controls.

  1995cited by this paper
• Haemostatic Effects of Supraphysiological Levels of Testosterone in Normal Men

  1995cited by this paper
• Mechanisms of physiological fibrinolysis.

  1995cited by this paper
• Fibrinolysis in Disease Molecular and Hemovascular Aspects of Fibrinolysis

  1995cited by this paper
• The Effects of Transdermal Estradiol and Oral Conjugated Estrogens on Haemostasis Variables

  1994cited by this paper
• Endogenous testosterone, fibrinolysis, and coronary heart disease risk in hyperlipidemic men.

  1993cited by this paper
• Venous Occlusion Does Not Release von Willebrand Factor, Factor VIII or PAI-1 from Endothelial Cells – The Importance of Consensus on the Use of Correction Factors for Haemoconcentration

  1993cited by this paper
• Effects of different oral oestrogen formulations on insulin‐like growth factor‐I, growth hormone and growth hormone binding protein in post‐menopausal women

  1993cited by this paper
• Androgen conjugates: physiology and clinical significance.

  1993cited by this paper
• Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor is an hepatic receptor for tissue-type plasminogen activator.

  1992cited by this paper
• Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal Women

  1992cited by this paper
• Estrogen and coronary heart disease in women

  1991cited by this paper
• Estrogen and coronary heart disease in women.

  1991cited by this paper
• Short- and long-term effects of hormone replacement therapy (transdermal estradiol vs oral conjugated equine estrogens, combined with medroxyprogesterone acetate) on blood coagulation factors in postmenopausal women.

  1991cited by this paper
• Short- and long-term effects of hormone replacement therapy (transdermal estradiol vs oral conjugated equine estrogens, combined with medroxyprogesterone acetate) on blood coagulation factors in posimenopausal women

  1991cited by this paper
• Plasminogen Activators t-PA, u-PA and Its Inhibitor (PAI) in Normal Males and Females

  1991cited by this paper
• Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women.

  1991cited by this paper
• Studies on the mechanism of action of oral contraceptives with regard to fibrinolytic variables.

  1990cited by this paper
• lncrease of Tissue Plasminogen Activator in Limbs During Venous Occlusion : A Simple Haemodynamic Model

  1990cited by this paper
• Plasminogen activator inhibitor in plasma is related to testosterone in men.

  1989cited by this paper
• Plasminogen Activator Inhibitor 1: Biosynthesis and mRNA Level Are Increased by Insulin in Cultured Human Hepatocytes

  1989cited by this paper
• Pharmacology of contraceptive steroids: a brief review.

  1989cited by this paper
• Lean body mass estimation by bioelectrical impedance analysis: a four-site cross-validation study.

  1988cited by this paper
• Renal and Hepatic Handling of Endogenous Tissue-Type Plasminogen Activator (t-PA) and Its Inhibitor in Man

  1988cited by this paper
• Diminished release of tissue plasminogen activator during venous occlusion in manual workers

  1988cited by this paper
• 97 Separate and joint effect of physical activity and DDAVP infusion on the release of tissue plasminogen activator

  1988cited by this paper
• Age Dependence of Blood Fibrinolytic Components and the Effects of Low-Dose Oral Contraceptives on Coagulation and Fibrinolysis in Teenagers

  1988cited by this paper
• 225 The influence of fibrin formation and degradation on the kinetics of inhibition of tissue-type plasminogen activator (T-PA) by plasminogen activator inhibitor 1 (PAI-1)

  1988cited by this paper
• Efficacy of transdermal estradiol.

  1987cited by this paper
• Plasminogen activator inhibitor 1: development of a radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation.

  1987cited by this paper
• Effects of two low-dose oral contraceptives on circulating components of the coagulation and fibrinolytic systems.

  1987cited by this paper
• Inhibition of Tissue-Type Plasminogen Activator in Plasma of Women Using Oral Contraceptives and in Normal Women During a Menstrual Cycle

  1986cited by this paper
• Biologic effects of transdermal estradiol

  1986cited by this paper
• Pharmacokinetics and Effects on Fibrinolytic and Coagulation Parameters of Two Doses of Recombinant Tissue-Type Plasminogen Activator in Healthy Volunteers

  1986cited by this paper
• Biological effects of estradiol-17 beta in postmenopausal women: oral versus percutaneous administration.

  1986cited by this paper
• Standards of care: The hormonal and surgical sex reassignment of gender dysphoric persons

  1985cited by this paper
• Standards of care: the hormonal and surgical sex reassignment of gender dysphoric persons. Harry Benjamin International Gender Dysphonia Association.

  1985cited by this paper
• Comparison of hepatic impact of oral and vaginal administration of ethinyl estradiol.

  1985cited by this paper
• Modulation of Rapid Plasminogen Activator Inhibitor in Plasma by Stanozolol

  1984cited by this paper
• On the Use of Different Correction Factors for Hemoconcentration

  1983cited by this paper
• Comparison of pharmacodynamic properties of various estrogen formulations.

  1982cited by this paper
• SEX‐HORMONE‐BINDING GLOBULIN

  1974cited by this paper

• Hemostatic parameters in transgender women receiving gender-affirming hormone therapy: A shift to a cisgender female pattern?

  2025cites this paper
• The effect of gender-affirming hormone therapy (GAHT) on the risk of subclinical atherosclerosis in the transgender population: a systematic review.

  2023cites this paper
• To clot, or not to clot: The dilemma of hormone treatment options for menopause.

  2022cites this paper
• Standards of Care for the Health of Transgender and Gender Diverse People, Version 8

  2022cites this paper
• Gender-affirming estrogen therapy route of administration and cardiovascular risk: a systematic review and narrative synthesis.

  2022cites this paper
• Sex differences in thrombosis as it affects acute ischemic stroke.

  2022cites this paper
• Cardiovascular Risk Associated With Gender Affirming Hormone Therapy in Transgender Population

  2021cites this paper
• Homocysteine: Its Possible Emerging Role in At-Risk Population Groups

  2020cites this paper
• A comparison of 5-year administration of cyproterone acetate or leuprolide acetate in combination with estradiol in transwomen.

  2020cites this paper
• Association of Surgical Risk With Exogenous Hormone Use in Transgender Patients: A Systematic Review

  2019cites this paper
• Gender-Affirming Hormone Therapy, Vascular Health and Cardiovascular Disease in Transgender Adults

  2019cites this paper
• Effects of sex steroids on cardiovascular risk profile in transgender men under gender affirming hormone therapy.

  2019cites this paper
• Cardiometabolic Effects of Testosterone in Transmen and Estrogen Plus Cyproterone Acetate in Transwomen

  2019cites this paper
• Cardiovascular disease in transgendered people: A review of the literature and discussion of risk

  2019cites this paper
• Cardiovascular health in transgender people

  2018cites this paper
• Gender dysphoria and transgender medicine in the year 2018

  2018cites this paper
• Sex Steroids and Cardiovascular Outcomes in Transgender Individuals: A Systematic Review and Meta‐Analysis

  2017cites this paper
• Cardiovascular disease in transsexual persons treated with cross-sex hormones: reversal of the traditional sex difference in cardiovascular disease pattern.

  2014cites this paper
• Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the European network for the investigation of gender incongruence.

  2014cites this paper
• Clinical effects of cross-sex hormone therapy in adult trans persons

  2014cites this paper
• The estrogenic burden on vascular risk in male-to-female transsexuals.

  2010cites this paper
• Effect of sex steroid use on cardiovascular risk in transsexual individuals: a systematic review and meta‐analyses

  2010cites this paper
• Etiological aspects, therapy regimes, side effects and treatment satisfaction of transsexual patients

  2009cites this paper
• Review of studies of androgen treatment of female-to-male transsexuals: effects and risks of administration of androgens to females.

  2008cites this paper
• Intraluminal-restricted 17 beta-estradiol exerts the same myocardial protection against ischemia/reperfusion injury in vivo as free 17 beta-estradiol.

  2008cites this paper
• Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience.

  2008cites this paper
• CLINICAL REVIEW 161 Endocrine Treatment of Transsexual People: A Review of Treatment Regimens, Outcomes, and Adverse Effects

  2007cites this paper
• Le traitement hormonal des patients transsexuels et ses conséquences métaboliques

  2007cites this paper
• [Hormonal treatment in transsexual patients. Metabolic consequences].

  2007cites this paper
• The effects of sex-steroid administration on the pituitary-thyroid axis in transsexuals.

  2006cites this paper
• Influence of exogenous oestrogen or (anti-) androgen administration on soluble transferrin receptor in human plasma.

  2005cites this paper
• Angiotensin-Converting Enzyme Inhibition Increases Basal Vascular Tissue Plasminogen Activator Release in Women But Not in Men

  2005cites this paper
• Activator Release in Women But Not in Men Angiotensin-Converting Enzyme Inhibition Increases Basal Vascular Tissue Plasminogen

  2005cites this paper
• The sex difference of plasma homovanillic acid is unaffected by cross-sex hormone administration in transsexual subjects.

  2005cites this paper
• Blood Rheology, Sex Hormones, and Cortisol in Athletes

  2004cites this paper
• Differential and Opposing Regulation of PAI-1 Promoter Activity by Estrogen Receptor &agr; and Estrogen Receptor &bgr; in Endothelial Cells

  2004cites this paper
• Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects.

  2003cites this paper
• Gender Differences in Methamphetamine-Induced mRNA Associated with Neurodegeneration in the Mouse Nigrostriatal Dopaminergic System

  2003cites this paper
• Risks and benefits of hormone replacement therapy: the evidence speaks.

  2003cites this paper
• Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people.

  2003cites this paper
• Acute and chronic effects of oestrogen on endothelial tissue‐type plasminogen activator release in postmenopausal women

  2003cites this paper
• Estrogen and neuroprotection: from clinical observations to molecular mechanisms

  2002cites this paper
• Comparative Effects of Estrogen and Angiotensin-Converting Enzyme Inhibition on Plasminogen Activator Inhibitor-1 in Healthy Postmenopausal Women

  2002cites this paper
• Über das therapeutische Potential von Estrogenen beim Mann

  2002cites this paper
• Plasminogen Activator Inhibitor‐1: Physiologic Role, Regulation, and the Influence of Common Pharmacologic Agents

  2002cites this paper
• Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.

  2002cites this paper
• The renin-angiotensin-aldosterone system and fibrinolysis in progressive renal disease.

  2002cites this paper
• Agents which Increase Synthesis and Release of Tissue-Type Plasminogen Activator

  2001cites this paper
• Sex differences and the effects of sex hormones on hemostasis and vascular reactivity.

  2001cites this paper
• Decreased synthesis of tissue plasminogen activator antigen in users of oral contraceptives

  2000cites this paper
• Oral Ethinyl Estradiol, but not Transdermal 17β-estradiol, Increases Plasma C-reactive Protein Levels in Men

  2000cites this paper
• Online-datenbank Mit Autoren-und Stichwortsuche Krause & Pachernegg Gmbh Verlag Für Medizin Und Wirtschaft A-3003 Gablitz Therapeutisches Potential Von Estrogenen

  year unknowncites this paper